Phase 3 Readout

TPST: Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezol

Name: Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezol
Start: 2030-07-01
End: 2030-07-01

July 1, 2030 · tpst-1120. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: July 1, 2030
Company: Tempest Therapeutics, Inc. (TPST)
Drug: tpst-1120

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezol

July 1, 2030

TPST overview →

Company: Tempest Therapeutics, Inc. (TPST)
Drug: tpst-1120
Indication: Hepatocellular Carcinoma (HCC)